-

Bayer to Present Updates on Pharma Growth Strategy and Pipeline Advancements at J.P. Morgan’s 44th Annual Healthcare Conference

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer will participate in the 44th J.P. Morgan Healthcare Conference 2026 taking place from January 12–15, 2026 in San Francisco. Stefan Oelrich, Member of the Board of Management, Bayer AG, and President of Bayer’s Pharmaceuticals Division, will present updates on the company’s pharmaceutical growth strategy and pipeline advancements across its portfolio.

The presentation will take place on Tuesday, January 13, 2026, from 11:15 to 11:55 PST. Investors, analysts, media professionals and members of the life sciences industry are invited to join the live webcast of the presentation via this link. Following the event, the webcast will also be made available with materials related to the presentation on Bayer's website.

About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2024, the Group employed around 93,000 people and had sales of 46.6 billion euros. R&D expenses amounted to 6.2 billion euros. For more information, go to www.bayer.com.

Find more information at https://pharma.bayer.com/
Follow us on Facebook: http://www.facebook.com/bayer
Follow us on X: @BayerPharma

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports, which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Contacts

Media Contact:
Elaine Colón
Bayer Media Relations
elaine.colon@bayer.com
+1-732-236-1587

Bayer

GER:BAYN

Release Versions

Contacts

Media Contact:
Elaine Colón
Bayer Media Relations
elaine.colon@bayer.com
+1-732-236-1587

More News From Bayer

Bayer to Invest 2.2 Billion U.S. Dollars in a New Manufacturing Site in the United States

NEW ALBANY, Ohio--(BUSINESS WIRE)--Bayer announced on Friday plans to invest 2.2 billion U.S. dollars in a new pharmaceutical manufacturing site in New Albany, Ohio, U.S. Building on more than seven billion dollars in U.S. pharma R&D and manufacturing spend over the past five years, the project is a central element of Bayer’s long-term growth strategy and commitment to innovation and patient access in its largest pharmaceuticals market. “Bayer has long seen the United States as a key manufa...

Alka-Seltzer Plus® to Relaunch as Alka-Seltzer™ Cold in 2026, Bringing Simpler Shopping and More Value to the Cough/Cold Aisle

WHIPPANY, N.J.--(BUSINESS WIRE)--Alka-Seltzer Plus® will relaunch in 2026 as Alka-Seltzer™ Cold, introducing a more intuitive brand architecture, simplified packaging and value-focused options designed to make the cough/cold aisle easier to shop. The relaunch reflects a sharper focus on the moments when consumers are sick, pressed for time and looking for trusted solutions that are easy to understand and accessible at the shelf. Key facts at a glance - New brand name: Alka-Seltzer™ Cold, replac...

MiraSOFT™ Launch at CVS Pharmacy, Expanding the MIRA Portfolio with a Stool Softener Option

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced the launch of MiraSOFT, a new stool softener option from the makers of MiraLAX® with the active ingredient docusate sodium designed to help gently soften hard, dry stools and support more comfortable, easier bowel movements. * MiraSOFT is now available at over 7,000 CVS Pharmacy locations and at cvs.com. Availability and where to find MiraSOFT at CVS Pharmacy: Retail footprint: Over 7,000 CVS Pharmacy stores and cvs.com In-store location: D...
Back to Newsroom